Siems WG, van Kuijk FJ, Maass R, Brenke R
Through its ability to affect miRNA expression and mRNA targets as well as epigenetic modulation, GT catechins contribute to the inhibition of prostate carcinogenesis
Ingredients: Water/Eau, Macadamia Ternifolia Seed Oil, Isocetyl Stearoyl Stearate, Parfum/Fragrance, Glycerin, Olea Europaea (Olive) Fruit Oil, Dimethicone, Glyceryl Stearate, Hexamethylindanopyran, PEG-100 Stearate, Cetearyl Alcohol, Cetyl Alcohol, Butyrospermum Parkii (Shea) Butter, Polysorbate 60, Stearic Acid, Caprylyl Glycol, Chlorphenesin, Tocopheryl Acetate, Xanthan Gum, Hexyl Cinnamal, Linalyl Acetate, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Linalool, Citrus Aurantium Bergamia (Bergamot) Peel Oil, Trisodium Ethylenediamine Disuccinate, Sodium Hydroxide, Lavandula Oil/Extract, Limonene, Hydroxycitronellal, Pinene, Camphor, Beta-Caryophyllene, Phytosteryl/Octyldodecyl Lauroyl Glutamate, Tocopherol
Premium peptides backed by consistency and uncompromising quality
AOD 9604 failed to achieve regulatory approval after early trials, and retatrutide remains in Phase 3 development without NICE or MHRA guidance
